Trial · NCT02616146
Results by group40
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 40
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of In-Treatment Pregnancies Per 100 Woman-Years of Exposure in Participants 18-35 Years of Age (Pearl Index) | ENG-E2 125 μg/300 μg | 1.54 | Pregnancies per 100 woman years | ||
| Number of In-Treatment Pregnancies Per 100 Woman-Years of Exposure in Participants 18-35 Years of Age (Pearl Index) | LNG-EE 150 μg/30 μg | 2.93 | Pregnancies per 100 woman years | ||
| Number of Participants Who Experienced an Adverse Event (AE) | ENG-E2 125 μg/300 μg | 530 | Participants | ||
| Number of Participants Who Experienced an Adverse Event (AE) | LNG-EE 150 μg/30 μg | 140 | Participants | ||
| Number of Participants Who Discontinued Treatment Due to an AE | ENG-E2 125 μg/300 μg | 61 | Participants | ||
| Number of Participants Who Discontinued Treatment Due to an AE | LNG-EE 150 μg/30 μg | 23 | Participants | ||
| Number of Participants With Breakthrough Bleeding/Spotting (BTB-S), by Cycle | ENG-E2 125 μg/300 μg | Cycle 2 | 166 | Participants | |
| Number of Participants With Breakthrough Bleeding/Spotting (BTB-S), by Cycle | LNG-EE 150 μg/30 μg | Cycle 2 | 54 | Participants | |
| Number of Participants With Breakthrough Bleeding/Spotting (BTB-S), by Cycle | ENG-E2 125 μg/300 μg | Cycle 3 | 112 | Participants | |
| Number of Participants With Breakthrough Bleeding/Spotting (BTB-S), by Cycle | LNG-EE 150 μg/30 μg | Cycle 3 | 36 | Participants | |
| Number of Participants With Breakthrough Bleeding/Spotting (BTB-S), by Cycle | ENG-E2 125 μg/300 μg | Cycle 4 | 79 | Participants | |
| Number of Participants With Breakthrough Bleeding/Spotting (BTB-S), by Cycle | LNG-EE 150 μg/30 μg | Cycle 4 | 20 | Participants | |
| Number of Participants With Breakthrough Bleeding/Spotting (BTB-S), by Cycle | ENG-E2 125 μg/300 μg | Cycle 5 | 42 | Participants | |
| Number of Participants With Breakthrough Bleeding/Spotting (BTB-S), by Cycle | LNG-EE 150 μg/30 μg | Cycle 5 | 13 | Participants | |
| Number of Participants With Breakthrough Bleeding/Spotting (BTB-S), by Cycle | ENG-E2 125 μg/300 μg | Cycle 6 | 29 | Participants | |
| Number of Participants With Breakthrough Bleeding/Spotting (BTB-S), by Cycle | LNG-EE 150 μg/30 μg | Cycle 6 | 8 | Participants | |
| Number of Participants With Breakthrough Bleeding/Spotting (BTB-S), by Cycle | ENG-E2 125 μg/300 μg | Cycle 7 | 13 | Participants | |
| Number of Participants With Breakthrough Bleeding/Spotting (BTB-S), by Cycle | LNG-EE 150 μg/30 μg | Cycle 7 | 7 | Participants | |
| Number of Participants With Breakthrough Bleeding/Spotting (BTB-S), by Cycle | ENG-E2 125 μg/300 μg | Cycle 8 | 8 | Participants | |
| Number of Participants With Breakthrough Bleeding/Spotting (BTB-S), by Cycle | LNG-EE 150 μg/30 μg | Cycle 8 | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02616146/results